AbbVie Inc. reported financial results for the third quarter ended September 30, 2026, showing a 10.3 percent increase in worldwide net revenues to $17.404 billion. On an operational basis, which adjusts for foreign exchange, revenues grew by 10.5 percent.
On a GAAP basis, diluted earnings per share (EPS) for the quarter were $2.37. Adjusted diluted EPS, excluding specified items, was $3.82. The company noted that these results include an unfavorable impact of $0.11 per share related to acquired intellectual property and research and development (IPR&D) and milestone expenses.
Revenue performance varied by business segment. The Immunology portfolio generated $9.165 billion, a 16.3 percent increase on a reported basis. Within this segment, Skyrizi generated $5.776 billion, an increase of 22.7 percent, while Rinvoq generated $2.706 billion, an increase of 23.9 percent. Conversely, Humira revenues were $683 million, a decrease of 31.2 percent.
The Neuroscience portfolio reported $3.389 billion in net revenues, up 19.4 percent. Key drivers included Vraylar at $1.068 billion and Botox Therapeutic at $1.080 billion. The Oncology portfolio generated $1.696 billion, up 0.8 percent, driven by Venclexta at $803 million. The Aesthetics portfolio reported $1.176 billion, down 1.4 percent.
AbbVie has raised its fiscal 2026 Adjusted Diluted EPS guidance range from $13.76 to $13.96 to $13.95 to $13.99. The company noted that the new range includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter.
In other corporate news, AbbVie announced it has completed the acquisition of Apogee Therapeutics. The company also announced a 5.2 percent increase to its 2027 dividend, with the first increased dividend payable in February 2027.
